drugset / Trial / NCT03840278
The Bihormonal iLet Bionic Pancreas Feasibility Study
Phase 2/3
Completed
12 enrolled
Massachusetts General Hospital
Beta Bionics, Inc. · collabZealand Pharma · collab
RandomizedCrossoverOpen-labelTreatment
Summary
Our objective is to evaluate the function of the bihormonal configuration of the ILet bionic pancreas delivering dasiglucagon when compared to the insulin-only configuration of the ILet bionic pancreas in a home-use study in adults with type 1 diabetes.
Timeline
- Start
- 2019-05-15
- Primary completion
- 2019-07-03
- Completion
- 2019-07-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dasiglucagon | Peptide | — | — |